These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2217473)

  • 21. Advanced prostate cancer: what's new in hormonal manipulation?
    Brewster SF; Gillatt DA
    Br J Hosp Med; 1993 May 19-Jun 1; 49(10):710-1, 714-5. PubMed ID: 7686805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hormone therapy in cancer.
    Kennedy BJ
    Geriatrics; 1970 Oct; 25(10):106-12. PubMed ID: 4096937
    [No Abstract]   [Full Text] [Related]  

  • 23. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
    Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
    Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer.
    Bolla M; Descotes JL; Artignan X; Fourneret P
    BJU Int; 2007 Jul; 100 Suppl 2():44-7. PubMed ID: 17594359
    [No Abstract]   [Full Text] [Related]  

  • 25. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapeutic options in advanced cancer of the prostate].
    Schmid HP; Bitton A
    Praxis (Bern 1994); 1997 Oct; 86(44):1734-9. PubMed ID: 9446174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Medical treatment of prostate cancer].
    Lobel B; Cipolla B; Labrador J
    Rev Prat; 1994 Mar; 44(5):611-5. PubMed ID: 8066398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma].
    Bruchovsky N; Goldenberg SL; Rennie PS; Gleave M
    Urologe A; 1995 Sep; 34(5):389-92. PubMed ID: 7483155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The immunotherapy of prostatic cancer].
    Murav'ev VB; Al'tvaĭn IE
    Urol Nefrol (Mosk); 1997; (4):46-8. PubMed ID: 9381625
    [No Abstract]   [Full Text] [Related]  

  • 31. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
    Palmberg C; Koivisto P; Kakkola L; Tammela TL; Kallioniemi OP; Visakorpi T
    J Urol; 2000 Dec; 164(6):1992-5. PubMed ID: 11061898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy.
    Gunawardana DH; Lichtenstein M; Better N; Rosenthal M
    Clin Nucl Med; 2004 Feb; 29(2):81-5. PubMed ID: 14734902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen depletion/repletion in combination with chemotherapy: strategy for secondary treatment of metastatic prostatic cancer.
    Santen RJ; English H; Rohner T; Drago J; Lipton A; Harvey H; Simmonds M; Boucher A; Glode LM; Wettlaufer J
    Prog Clin Biol Res; 1985; 185A():359-71. PubMed ID: 4034580
    [No Abstract]   [Full Text] [Related]  

  • 34. The treatment of hormone refractory prostate cancer.
    Panvichian R; Pienta KJ
    Compr Ther; 1996 Feb; 22(2):81-7. PubMed ID: 8689867
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluation of aminoglutethimide in stage D prostate cancer: an assessment of efficacy and toxicity in patients with tumors refractory to hormonal therapy.
    Block M; Trump D; Rose DP; Cummings KB; Hogan TF
    Cancer Treat Rep; 1984 May; 68(5):719-22. PubMed ID: 6722829
    [No Abstract]   [Full Text] [Related]  

  • 36. [Antineoplastic chemotherapies (including hormone therapy). Classification and mechanism of action].
    Clavel M
    Rev Prat; 1991 Dec; 41(26):2759-65. PubMed ID: 1808694
    [No Abstract]   [Full Text] [Related]  

  • 37. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F; Dupont A; Belanger A
    Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
    [No Abstract]   [Full Text] [Related]  

  • 38. [The immune homeostasis of patients with prostatic cancer on hormonal chemotherapy, radiation treatment and immunological action].
    Panteleeva ES; Sviridova TV; Neprina GS; Sirotkina NP
    Urol Nefrol (Mosk); 1996; (1):28-31. PubMed ID: 8659039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [What is safe in the therapy of advanced prostatic cancer?].
    Gropp C; Burk K
    Internist (Berl); 1985 Dec; 26(12):765-70. PubMed ID: 3936819
    [No Abstract]   [Full Text] [Related]  

  • 40. [Chemotherapy in prostatic carcinoma].
    Pérez Manga G; Arranz Arija JA; García Gómez R; Salinas Hernández P; González del Val R
    Arch Esp Urol; 1993 Mar; 46(2):116-26. PubMed ID: 8498851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.